This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mugnier, P.
Right arrow Articles by Collatz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mugnier, P.
Right arrow Articles by Collatz, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3113-3116, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Novel OXA-10-Derived Extended-Spectrum beta -Lactamases Selected In Vivo or In Vitro

P. Mugnier,1,dagger I. Casin,1,2 A. T. Bouthors,1 and E. Collatz1,*

Laboratoire de Recherche Moléculaire sur les Antibiotiques, UFR Broussais-Hôtel Dieu and UFR Pitié-Salpêtrière, Université Paris VI,1 and Laboratoire de Bactériologie, Hôpital Saint-Louis, Université Paris VII,2 Paris, France

Received 25 February 1998/Returned for modification 3 June 1998/Accepted 20 September 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

A clinical isolate of Pseudomonas aeruginosa, PAe191, was found to be highly resistant to all anti-Pseudomonas beta -lactam antibiotics (except imipenem) and resistant also to aminoglycosides. It produced a beta -lactamase (with an apparent pI of 7.6) which was not inhibited by clavulanic acid. Cloning and characterization of the beta -lactamase gene showed that it coded for a novel extended-spectrum OXA-10 variant, called OXA-19, which differed from OXA-10 by nine amino acids and from OXA-13 by two, i.e., Asn in position 73 (Asn73) instead of Ser and Asp157 instead of Gly. Asparagine in position 157 is implicated in resistance to ceftazidime, while the amino acid in position 73, in this variant, seems to condition the level of resistance to penicillins. The oxa19 gene was found to be inserted, in a typical integron structure, immediately downstream from an aac(6')-Ib gene coding for an aminoglycoside acetyltransferase variant, which was called AAC(6')-Ib9.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

A major mechanism of resistance of Pseudomonas aeruginosa to cephalosporins used in clinical practice, such as cefsulodin or ceftazidime, is the overproduction of its cephalosporinase, resulting from depression of the ampC transcription inhibition pathway (14). Alternatively, resistance to the broad-spectrum cephalosporins, including ceftazidime and cefepime, may result from the production of an extended-spectrum beta -lactamase (ESBL). In P. aeruginosa, as opposed to members of the family Enterobacteriaceae, production of TEM- and SHV-type ESBLs (3) seems to be rare (22), and other extended-spectrum enzymes, such as PER-1 (23), OXA-2-, or OXA-10-derived ESBLs (8-10), and a clavulanic acid-susceptible class D enzyme, OXA-18 (24), have been described for clinical strains of this species. The enzymes of molecular class D (13) comprise those of group 2d of the functional classification scheme described by Bush et al. (3) and are characterized by high relative rates of oxacillin hydrolysis and generally low susceptibility to inhibition by clavulanic acid (3, 18). Like the other active-site serine beta -lactamases, the class D enzymes have at least three conserved amino acid motifs, which are shown in Fig. 1 for the OXA-10 derivatives.


View larger version (11K):
[in this window]
[in a new window]
  		FIG. 1.   Amino acid differences between the beta -lactamases of the OXA-10 group. Amino acid numbering is according to Huovinen et al. (13); the conserved motifs typical for class D enzymes are boxed. The amino acids shown in boldface contribute to the substrate profile, with asparagine in position 157 leading to extended-spectrum variants. The amino acids of OXA-10 that are not numbered are G20, S27, S50, D55, V89, T107, Y174, A197, E229, T230, S245, and E259; -, absence of an amino acid.

High-resolution crystallography studies of several class A penicillinases (34) have generated a basis for understanding the molecular mechanisms underlying the substrate profile extensions secondary to a large array of point mutations in TEM- or SHV-type ESBLs (16, 26). For the class D enzymes, no such studies have been reported, and only two amino acid changes have been implicated in the extension of the substrate profiles to ceftazidime, i.e., Gly157 to Asp in the OXA-10-derived OXA-11 (10) and OXA-14 (8) and Asp150 to Gly in the OXA-2-derived OXA-15 (9). These positions are, respectively, 14 and 2 amino acids downstream from the YGN triad in the OXA-10 and OXA-2 derivatives (6, 8-10, 13) (Fig. 1). Here, we describe a novel ESBL, OXA-19, from a clinical P. aeruginosa isolate, containing nine altered amino acids with respect to the non-ESBL OXA-10 (13) and two altered amino acids with respect to the non-ESBL OXA-13 (20), both of which appear to contribute to the level of resistance to anti-Pseudomonas penicillins and cephalosporins in Escherichia coli and P. aeruginosa.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Strains and plasmids. The strains and plasmids used are summarized in Table 1. P. aeruginosa PAe191 was isolated in 1991 at the Saint-Louis Hospital, Paris, France. This strain was highly resistant to ceftazidime (MIC, 512 µg/ml). Strain PAO38(pAZ310) was selected on ceftazidime (16 µg/ml) from strain PAO38(pAZ309), which was described previously (20). Strains were grown in Mueller-Hinton (MH) medium at 37°C.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Strains and plasmids

MIC determinations and antibiotics. MICs on MH agar containing serially twofold-diluted antibiotics were determined. Plates inoculated with a Steers-type inoculator and ca. 104 CFU per spot were incubated at 37°C for 18 h. The MICs of beta -lactams were determined alone or in combination with imipenem (0.25 µg/ml), clavulanic acid (2 µg/ml), or tazobactam (4 µg/ml). MIC determinations were repeated twice, with identical results. Antibiotics were provided from the following suppliers: ampicillin, aztreonam, and amikacin, Bristol Myers Squibb; ceftazidime, Glaxo Group Research, Ltd.; cefotaxime, Hoechst Roussel Pharmaceuticals Ltd.; piperacillin and tazobactam, Lederle Laboratories; imipenem, Merck Sharp and Dohme-Chibret; gentamicin, Schering Plough; clavulanic acid and ticarcillin, SmithKline Beecham; and cefsulodin, Takeda Laboratories.

beta -Lactamase preparation. Crude enzyme (S100) extracts were prepared as previously described (20). The supernatants were used immediately for the determination of kinetic parameters and isoelectric points. The protein concentrations were measured by the technique described by Bradford (2), and the hydrolysis rates in phosphate buffer (50 mM, pH 7.0) were determined spectrophotometrically at 30°C with a model 550S double-beam spectrophotometer (Perkin-Elmer), with ampicillin and ceftazidime as the substrates. One unit of beta -lactamase was defined as the amount hydrolyzing 1 µmol of substrate per min.

IEF. Isoelectric focusing (IEF) of S100 extracts was for 2 h, with a mini-IEF cell 111 (Bio-Rad) and a gradient made up of two-thirds polyampholytes with a pH range of 3 to 9 and one-third of polyampholytes with a pH range of 2 to 11 (Serva). Extracts from OXA-10-, SHV-1-, and SHV-5-producing strains were used as standards for pIs of 6.1, 7.6, and 8.2, respectively. beta -Lactamases were revealed by overlay with nitrocefin (1 mg/ml) in phosphate buffer (50 mM, pH 7.0).

Cloning experiments and DNA sequencing. Standard DNA methodology (1) was used to clone two ca. 4.0-kb HindIII DNA fragments carrying either the in vitro-selected ESBL gene oxa13-1 or the in vivo-selected gene oxa19 (Table 1) (20) into the pNJR3-2 shuttle vector, allowing the expression of both genes in P. aeruginosa PAO38. These fragments were also cloned into M13mp18 and M13mp19 phage vectors and were partially sequenced as described previously (20). The sequenced stretches which have been determined for oxa19 and oxa13-1 and their adjacent integron regions are represented schematically in Fig. 1. The -35 sequences of the promoter of the aac(6')-Ib, oxa13-1 cistron were taken to be identical with that of the original oxa13-containing integron (20). For expression of the two ESBL genes in an isogenic E. coli background, both genes were cloned on a NarI-HindIII fragment into the vector pK18.

Nucleotide sequence accession numbers. The nucleotide sequences for oxa19 [including aac(6')-Ib] and oxa13-1 have been deposited in GenBank under accession numbers AF043381 and AF043558, respectively.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Resistance phenotypes of PAe191 and PAO38(pAZ316). PAe191 was resistant to all anti-Pseudomonas beta -lactam antibiotics tested, except imipenem, and also to aminoglycosides, sulfonamides, and mercuric ions. Ticarcillin, piperacillin, and ceftazidime were not protected when associated with a beta -lactamase inhibitor, such as clavulananic acid or tazobactam. However, the high-level resistance of PAe191 to ceftazidime was reversed by imipenem (Table 2). The protective effect of imipenem on otherwise hydrolyzed beta -lactam compounds in P. aeruginosa has been previously observed in the presence of OXA-10-related enzymes (20). In order to characterize the beta -lactamase responsible for this phenotype and the nucleotide sequences controlling its production, a ca. 4.0-kb HindIII fragment from PAe191 DNA was cloned into pNJR3-2, yielding pAZ316 (Table 1). PAO38(pAZ316) showed the same beta -lactam resistance pattern as that of PAe191, and a MIC of gentamicin greater than that of amikacin was observed. Both PAe191 (see Fig. 3, lane 3) and PAO38(pAZ316) (data not shown) produced only one beta -lactamase, with an apparent pI (pIapp) of 7.6, which was then likely to be an ESBL. No plasmid was found in the clinical strain PAe191 despite the use of techniques (15, 35) allowing the extraction of large plasmids, such as the OXA-1-encoding plasmid RGN238 (12).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   MICs of different beta -lactams for PAe191 and OXA13-1, OXA-19- and OXA-13-producing transformants

Nucleotide sequence of the gene cluster encoding aminoglycoside and beta -lactam resistance in PAe191. Sequence analysis of a ca. 2-kb fragment from pAZ316 revealed the presence of two resistance genes, each flanked by a recombinational element at its 3' extremity, which is typical of those found in the resistance gene cassettes in integrons (11, 30, 33). Only four mutations (Fig. 1) were observed in comparison with the sequence of a very similar integron-borne cluster described previously (20). The first was in the -35 sequence of the promoter P1, located within the integrase gene intI1, which controls the expression of the resistance genes (33). The three other mutations were in the resistance genes themselves. The gene immediately downstream from intI1 encoded an AAC(6')-Ib variant, called AAC(6')-Ib9, with a Leu-to-Ser change at position 119 with respect to the otherwise identical AAC(6')-Ib protein encoded by pAZ301 (20) and to other typically amikacin resistance-conferring variants (36). This amino acid change has been associated previously with a shift from amikacin to gentamicin resistance in vitro after site-directed mutagenesis (27) and in clinical isolates of Pseudomonas fluorescens (17) and Enterobacteriaceae (4). The second resistance gene had two nucleotide differences accounting for two amino acid differences in comparison with OXA-13 (Fig. 1 and 2) (20), with Asn73 instead of Ser and Asp157 instead of Gly. This novel variant was named OXA-19. As already mentioned, Asp157 has been associated previously with the extension of the beta -lactam resistance spectrum to ceftazidime (8, 10, 21).


View larger version (9K):
[in this window]
[in a new window]
  		FIG. 2.   Structure of the integron encoding the beta -lactamases OXA-19 and OXA-13-1. Nucleotide sequences are identical in both clusters, except for three differences in the -35 sequences of the promoter and in the aac(6')-Ib and the oxa genes. Amino acid numbering is from Tran Van Nhieu and Collatz (36) and Huovinen et al. (13), respectively. Arrows represent the following open reading frames: intI1, for integrase; aac(6')-Ib, for the aminoglycoside acetyltransferases genes aac(6')-Ib10 on pAZ310 (20) and aac(6')-Ib9 on pAZ316; oxa, for the OXA variants indicated on the left; and qacEDelta 1, for the typically truncated quaternary ammonium resistance-conferring gene associated with the 3' conserved segment of integrons. The intI1 and qacEDelta 1 genes have been only partially sequenced here (indicated in boldface). Data for pAZ309 are from reference 20, and data for pAZ310 and pAZ316 are from the present study. Boldface, differences with respect to the OXA-13-encoding plasmid pAZ309; dashed line, the oxa13-1 region that has been sequenced.

Selection in vitro and characterization of an ESBL variant of OXA-13. To determine whether a derivative of OXA-13 conferring the resistance phenotype of OXA-19 in P. aeruginosa could be generated by a point mutation, a spontaneous mutant of PAO38(pAZ309), which was called PAO38(pAZ310), was selected on ceftazidime (Table 1). An OXA variant of pIapp 7.8 was obtained (Fig. 3). It differed from OXA-13 by only a Gly157-to-Asp change and was named OXA-13-1. Although the production of this enzyme in PAO38(pAZ310) led to a resistance pattern similar to that of OXA-19 in PAO38(pAZ316) (Table 2), the level of resistance of PAO38(pAZ316) to some of the beta -lactams tested, especially ticarcillin and piperacillin, appeared to be higher than that of PAO38(pAZ310). In repeated assays, the MIC of ampicillin for a pAZ316-containing E. coli strain was also found to be four times as high as that for the same strain containing pAZ310 (data not shown). These observations could be related to a ca. 30-times-higher specific activity of OXA-19 against ampicillin, in comparison with OXA-13-1 (Table 3), while the specific activities of both enzymes against ceftazidime were similar.


View larger version (94K):
[in this window]
[in a new window]
  		FIG. 3.   Isoelectric focusing of extended-spectrum OXA-10-related beta -lactamases. Enzymes SHV-1 (pIapp, 7.6), SHV-5 (pIapp, 8.2), OXA-13 (pIapp, 8 [18]), and OXA-10 (pIapp, 6.1) were used as pI standards. The two novel beta -lactamases, OXA-13-1 and OXA-19, had estimated pIapps of 7.8 and 7.6, respectively. beta -Lactamase activity was revealed by overlaying the gel with nitrocefin.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Specific activities of OXA-13-1 and OXA-19 from P. aeruginosa and E. coli producers

Effect of Asn or Ser in position 73 on the level of resistance to penicillins in OXA-19 and OXA-13-1 producers. Two of the three nucleotide differences that distinguish the aac(6')-Ib, oxa clusters of pAZ316 and pAZ310 (Fig. 2) could be involved in modulating the levels of penicillin resistance, the difference in the -35 promoter sequence and that concerning amino acid position 73. Cloning of the NarI-HindIII fragments from both plasmids carrying oxa13-1 or oxa19 into pK18 yielded pAZ326 and pAZ327, respectively, leaving only the difference in position 73 (Fig. 2). It eliminated the likely difference in promoter strength (the -35 sequence TTGACA [Fig. 2] being known to occur in promoters stronger than TGGACA in E. coli [19]) and the possible influence of secondary-structure variations in the so-called 59-bp element (5) on oxa expression. Table 2 shows the beta -lactam resistance patterns of E. coli DH5alpha harboring pAZ326 or pAZ327. In these constructs, the higher MICs of penicillins for the OXA-19-producing strain correlated with a higher specific activity of OXA-19 against ampicillin in comparison with that of OXA-13-1 (Table 3). Thus, it is conceivable that Asn in position 73 conditions the level of resistance to beta -lactams, and to penicillins in particular, also for P. aeruginosa PAO38(pAZ316) and, hence, the clinical strain PAe191.

An asparagine is generally found at position 73 (numbering of Huovinen et al [13]) in OXA variants of the OXA-10 branch (13, 29), whether they are penicillinases, such as OXA-5 (5) or OXA-7 (31), or of the extended spectrum, such as OXA-11 (10), OXA-14 (8), or OXA-16 (7). Thus, OXA-13 seems to be a rather rare variant with respect to the amino acid in position 73. Although the effect of a serine at this position is not known in OXA-10 derivatives with a glycine in position 157 which have a penicillinase profile, its association with aspartate at position 157 in the ESBL OXA-13-1 seems to result in a relatively low level of resistance to penicillins and a relatively low level of penicillinase activity in the producing strains.

    ACKNOWLEDGMENT

This work was supported by a grant from the Institut National de la Santé et de la Recherche Médicale, Paris, France (CRI 95061).

    FOOTNOTES

* Corresponding author. Mailing address: L.R.M.A., Université Paris VI, 15, rue de l'Ecole de Médecine, 75270 Paris Cedex 06, France. Phone: 33-1-42 34 68.65. Fax: 33-1-43.25.68.12. E-mail: collatz{at}ccr.jussieu.fr.

dagger Present address: Department of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, United Kingdom.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). Current protocols in molecular biology. Greene Publishing Associates and Wiley Interscience, New York, N.Y.
2. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing a principle of protein-dye binding. Anal. Biochem. 72:248-254[Medline].
3. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta -lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233[Medline].
4. Casin, I., F. Bordon, P. Bertin, A. Coutrot, I. Podglajen, R. Brasseur, and E. Collatz. 1998. Aminoglycoside 6'-N-acetyltransferase variants of the Ib type with altered substrate profiles in clinical isolates of Enterobacter cloacae and Citrobacter freundii. Antimicrob. Agents Chemother. 42:209-215[Abstract/Free Full Text].
5. Collis, C. M., and R. M. Hall. 1995. Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob. Agents Chemother. 39:155-162[Abstract].
6. Couture, F., J. Lachapelle, and R. C. Levesque. 1992. Phylogeny of LCR-1 and OXA-5 with class A and class D beta -lactamases. Mol. Microbiol. 6:1693-1705[Medline].
7. Danel, F., L. M. C. Hall, and D. M. Livermore. 1997. Laboratory mutants of OXA-10 beta -lactamase giving ceftazidime resistance in Pseudomonas aeruginosa, abstr. no. C191. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1995. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta -lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1881-1884[Abstract].
9. Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1997. OXA-15, an extended-spectrum variant of OXA-2 beta -lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother. 41:785-790[Abstract].
10. Hall, L. M., D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin. 1993. OXA-11, an extended spectrum variant of OXA-10 (PSE-2) beta -lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:1637-1644[Abstract/Free Full Text].
11. Hall, R. M., and C. M. Collis. 1995. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. Mol. Microbiol. 15:593-600[Medline].
12. Hedges, R. W., N. Datta, P. Kontomichalou, and J. T. Smith. 1974. Molecular specificities of R factor-determined beta -lactamase: correlation with plasmid compatibility. J. Bacteriol. 117:56-62[Abstract/Free Full Text].
13. Huovinen, P., S. Huovinen, and G. A. Jacoby. 1988. Sequence of PSE-2 beta -lactamase. Antimicrob. Agents Chemother. 32:134-136[Abstract/Free Full Text].
14. Jacobs, C., L. J. Huang, E. Bartowsky, S. Normark, and J. T. Park. 1994. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta -lactamase induction. EMBO J. 13:1684-1694.
15. Kado, C. I., and S. T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. J. Bacteriol. 145:1365-1373[Abstract/Free Full Text].
16. Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type beta -lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601[Medline].
17. Lambert, T., M. C. Ploy, and P. Courvalin. 1994. A spontaneous point mutation in the aac(6')-Ib' gene results in altered substrate specificity of aminoglycoside 6'-N-acetyltransferase of a Pseudomonas fluorescens strain. FEMS Microbiol. Lett. 115:297-304[Medline].
18. Ledent, P., X. Raquet, B. Joris, J. van Beeumen, and J. M. Frère. 1993. A comparative study of class D beta -lactamases. Biochem. J. 292:555-562.
19. Lévesque, C., S. Brassard, J. Lapointe, and P. H. Roy. 1994. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene 142:49-54[Medline].
20. Mugnier, P., I. Podglajen, F. W. Goldstein, and E. Collatz. 1998. Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta -lactamase in Pseudomonas aeruginosa. Microbiology 144:1021-1031[Abstract/Free Full Text].
21. Mugnier, P., I. Podglajen, L. Gutmann, and E. Collatz. 1994. Cloning and nucleotide sequence analysis of two Pseudomonas aeruginosa genes encoding the novel OXA-type beta -lactamase variants OXA-12 and OXA-13, susceptible to inhibition by imipenem, abstr. no. C98. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Mugnier, P., P. Dubrous, I. Casin, G. Arlet, and E. Collatz. 1996. A TEM-derived extended-spectrum beta -lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:2488-2493[Abstract].
23. Nordmann, P., and T. Naas. 1994. Sequence analysis of PER-1 extended-spectrum beta -lactamase from Pseudomonas aeruginosa and comparison with class A beta -lactamases. Antimicrob. Agents Chemother. 38:104-114[Abstract/Free Full Text].
24. Philippon, L. N., T. Naas, A.-T. Bouthors, V. Barakett, and P. Nordmann. 1997. OXA-18, a class D clavulanic-acid inhibited extended spectrum beta -lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2188-2195[Abstract].
25. Pridmore, R. D. 1987. New and versatile cloning vectors with kanamycin-resistance marker. Gene 56:309-312[Medline].
26. Raquet, X., J. Lamotte-Brasseur, E. Fonzé, S. Goussard, P. Courvalin, and J. M. Frère. 1994. TEM beta -lactamase mutants hydrolysing third-generation cephalosporins. J. Mol. Biol. 244:625-639[Medline].
27. Rather, P. N., H. Munayyer, P. A. Mann, R. S. Hare, G. H. Miller, and K. J. Shaw. 1992. Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J. Bacteriol. 174:3196-3203[Abstract/Free Full Text].
28. Robillard, N. J. 1990. Broad-host-range gyrase A gene probe. Antimicrob. Agents Chemother. 34:1889-1894[Abstract/Free Full Text].
29. Sanschagrin, F., F. Couture, and R. C. Levesque. 1995. Primary structure of OXA-3 and phylogeny of oxacillin-hydrolyzing class D beta -lactamases. Antimicrob. Agents Chemother. 39:887-893[Abstract].
30. Schmidt, F. R. J., E. J. Nücken, and R. B. Henschke. 1989. Structure and function of hot spots providing signals for site-directed specific recombination and gene expression in Tn21 transposons. Mol. Microbiol. 3:1545-1555[Medline].
31. Scoulica, E., A. Aransay, and Y. Tselentis. 1995. Molecular characterization of the OXA-7 beta -lactamase gene. Antimicrob. Agents Chemother. 39:1379-1382[Abstract].
32. Seifert, S. H., M. So, and F. Heffron. 1986. Shuttle mutagenesis: a method of introducing transposons into transformable organisms, p. 128-134. In J. K. Setlow, and A. Hollander (ed.), Genetic engineering, principles and methods, vol. 8. Plenum, New York, N.Y.
33. Stokes, H. W., and R. M. Hall. 1989. A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: integrons. Mol. Microbiol. 3:1669-1683[Medline].
34. Strynadka, N. C. J., H. Adachi, S. E. Jensen, K. Johns, A. Sielecki, C. Betzel, K. Sutoh, and M. N. G. James. 1992. Molecular structure of the acyl-enzyme intermediate in beta -lactam hydrolysis at 1.7 Å resolution. Nature (London) 359:700-705[Medline].
35. Takahashi, S., and Y. Nagano. 1984. Rapid procedure for isolation of plasmid DNA and application to epidemiological analysis. J. Clin. Microbiol. 20:608-613[Abstract/Free Full Text].
36. Tran Van Nhieu, G., and E. Collatz. 1987. Primary structure of an aminoglycoside 6'-N-acetyltransferase, AAC(6')-4, fused in vivo with the signal peptide of the Tn3-encoded beta -lactamase. J. Bacteriol. 169:5708-5714[Abstract/Free Full Text].

Antimicrobial Agents and Chemotherapy, December 1998, p. 3113-3116, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lascols, C., Podglajen, I., Verdet, C., Gautier, V., Gutmann, L., Soussy, C.-J., Collatz, E., Cambau, E. (2008). A Plasmid-Borne Shewanella algae Gene, qnrA3, and Its Possible Transfer In Vivo between Kluyvera ascorbata and Klebsiella pneumoniae. J. Bacteriol. 190: 5217-5223 [Abstract] [Full Text]  
  • Depardieu, F., Podglajen, I., Leclercq, R., Collatz, E., Courvalin, P. (2007). Modes and Modulations of Antibiotic Resistance Gene Expression. Clin. Microbiol. Rev. 20: 79-114 [Abstract] [Full Text]  
  • Poole, K. (2005). Aminoglycoside Resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 479-487 [Full Text]  
  • Correia, M., Boavida, F., Grosso, F., Salgado, M. J., Lito, L. M., Cristino, J. M., Mendo, S., Duarte, A. (2003). Molecular Characterization of a New Class 3 Integron in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 47: 2838-2843 [Abstract] [Full Text]  
  • Casin, I., Hanau-Bercot, B., Podglajen, I., Vahaboglu, H., Collatz, E. (2003). Salmonella enterica Serovar Typhimurium blaPER-1-Carrying Plasmid pSTI1 Encodes an Extended-Spectrum Aminoglycoside 6'-N-Acetyltransferase of Type Ib. Antimicrob. Agents Chemother. 47: 697-703 [Abstract] [Full Text]  
  • De Champs, C., Poirel, L., Bonnet, R., Sirot, D., Chanal, C., Sirot, J., Nordmann, P. (2002). Prospective Survey of {beta}-Lactamases Produced by Ceftazidime- Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000. Antimicrob. Agents Chemother. 46: 3031-3034 [Abstract] [Full Text]  
  • Bert, F., Branger, C., Lambert-Zechovsky, N. (2002). Identification of PSE and OXA {beta}-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 50: 11-18 [Abstract] [Full Text]  
  • Poirel, L., Gerome, P., De Champs, C., Stephanazzi, J., Naas, T., Nordmann, P. (2002). Integron-Located oxa-32 Gene Cassette Encoding an Extended-Spectrum Variant of OXA-2 {beta}-Lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46: 566-569 [Abstract] [Full Text]  
  • Aubert, D., Poirel, L., Ben Ali, A., Goldstein, F. W., Nordmann, P. (2001). OXA-35 is an OXA-10-related {beta}-lactamase from Pseudomonas aeruginosa. J Antimicrob Chemother 48: 717-721 [Abstract] [Full Text]  
  • Bradford, P. A. (2001). Extended-Spectrum {beta}-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin. Microbiol. Rev. 14: 933-951 [Abstract] [Full Text]  
  • Poirel, L., Girlich, D., Naas, T., Nordmann, P. (2001). OXA-28, an Extended-Spectrum Variant of OXA-10 {beta}-Lactamase from Pseudomonas aeruginosa and Its Plasmid- and Integron-Located Gene. Antimicrob. Agents Chemother. 45: 447-453 [Abstract] [Full Text]  
  • Bou, G., Oliver, A., Martínez-Beltrán, J. (2000). OXA-24, a Novel Class D beta -Lactamase with Carbapenemase Activity in an Acinetobacter baumannii Clinical Strain. Antimicrob. Agents Chemother. 44: 1556-1561 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mugnier, P.
Right arrow Articles by Collatz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mugnier, P.
Right arrow Articles by Collatz, E.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»